Heart

• 

  Publication Venue For

  • Women, men and the safety gap after catheter ablation of atrial fibrillation. 2022
  • Sex-based differences in atrial fibrillation ablation adverse events. 2022
  • Management of cardiovascular risk factors during pregnancy..  108:1438-1444. 2022
  • Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial..  108:948-955. 2022
  • Systematic review of current natural language processing methods and applications in cardiology..  108:909-916. 2022
  • Physician judgement in predicting obstructive coronary artery disease and adverse events in chest pain patients..  108:860-867. 2022
  • Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis..  108:194-202. 2022
  • Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease..  107:1739-1747. 2021
  • Global health: where do cardiologists fit in?.  107:1678-1679. 2021
  • Towards a personalised approach for obesity treatment: one size does not fit all..  107:1526-1527. 2021
  • Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation..  107:713-720. 2021
  • Patterns of oral anticoagulation use with cardioversion in clinical practice..  107:642-649. 2021
  • Recreational substance use among patients with premature atherosclerotic cardiovascular disease..  107:650-656. 2021
  • Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation..  106:1919-1926. 2020
  • Ischaemic stroke in heart failure: back to basics?.  106:555-556. 2020
  • Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation..  106:358-364. 2020
  • Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia..  106:273-279. 2020
  • Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients..  105:1622-1628. 2019
  • Atrial fibrillation: what do we know about screening and what do we not know about treatment?.  105:817-819. 2019
  • A 26-year-old man with severe right ventricular hypertrophy..  105:774-789. 2019
  • B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation..  105:370-377. 2019
  • Hospital-based quality improvement interventions for patients with heart failure: a systematic review..  105:431-438. 2019
  • Can coronary computed tomography angiography be the complete roadmap for chronic total occlusion management?.  105:174-175. 2019
  • Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation..  105:235-242. 2019
  • Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation..  104:1850-1858. 2018
  • Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease..  104:1292-1299. 2018
  • Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease..  104:1144-1147. 2018
  • Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft surgery..  104:985-992. 2018
  • Disease understanding in patients newly diagnosed with atrial fibrillation..  104:494-501. 2018
  • The authors' reply to the letter from Kerkhof et al entitled 'The importance of (measuring) the end-systolic volume index in predicting survival'..  104:1. 2018
  • Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery..  103:1359-1367. 2017
  • Chocolate and prevention of atrial fibrillation: what is bad for the pancreas might be good for the atria?.  103:1141-1142. 2017
  • Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes..  103:1168-1176. 2017
  • Medication adherence: a moving target?.  103:1059-1060. 2017
  • Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?.  103:807-808. 2017
  • Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation..  103:623-628. 2017
  • Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure..  103:407-413. 2017
  • Loneliness and social isolation and increased risk of coronary heart disease and stroke: clinical implications..  102:2016. 2016
  • Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients..  102:1221-1229. 2016
  • Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban..  102:1036-1043. 2016
  • Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes..  102:882-892. 2016
  • A 28-year-old man with chest and joint pains..  102:808. 2016
  • Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation..  102:508-517. 2016
  • Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction..  102:527-533. 2016
  • Optimal non-invasive imaging test selection for the diagnosis of ischaemic heart disease..  102:555-564. 2016
  • Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention..  102:617-625. 2016
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy..  102:303-312. 2016
  • Measuring heart failure quality: does perfection matter?.  101:1691-1692. 2015
  • Chronic pacing and adverse outcomes after transcatheter aortic valve implantation..  101:1665-1671. 2015
  • Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement..  101:1656-1664. 2015
  • Adiponectin: an accurate biomarker for patients at risk for atrial fibrillation?.  101:1351-1352. 2015
  • Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome..  101:1475-1484. 2015
  • Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement..  101:1382-1388. 2015
  • Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials..  101:1309-1317. 2015
  • Heart rate is associated with progression of atrial fibrillation, independent of rhythm..  101:894-899. 2015
  • Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged..  101:692-698. 2015
  • Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low EF..  101:463-471. 2015
  • Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients..  101:264-270. 2015
  • Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome..  101:279-286. 2015
  • Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation..  100:1871-1877. 2014
  • Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial..  100:1543-1549. 2014
  • Short and long term effect of adjunctive intra-aortic balloon pump use for patients undergoing high risk reperfusion therapy: a meta-analysis of 10 international randomised trials..  100:303-310. 2014
  • Palpitations in a 64-year-old man..  100:167-168. 2014
  • The society of thoracic surgeons national database..  99:1494-1501. 2013
  • A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial..  99:1282-1287. 2013
  • Multiple cardiovascular risk factors in Kenya: evidence from a health and demographic surveillance system using the WHO STEPwise approach to chronic disease risk factor surveillance..  99:1323-1329. 2013
  • Medication, reperfusion therapy and survival in a community-based setting of hospitalised myocardial infarction..  99:767-773. 2013
  • Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis..  99:76-82. 2013
  • ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK..  98:865-871. 2012
  • Implantable cardioverter defibrillators: risks accompany the life-saving benefits..  98:764-772. 2012
  • The myocardial area at risk..  98:348-350. 2012
  • High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype..  98:343. 2012
  • Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction..  98:109-115. 2012
  • Safety of serial MRI in patients with implantable cardioverter defibrillators..  97:1852-1856. 2011
  • Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period..  97:1607-1618. 2011
  • Impact of early surgery on survival of patients with severe mitral regurgitation..  97:221-224. 2011
  • The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care..  96:1798-1802. 2010
  • Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial..  96:838-842. 2010
  • Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study..  96:190-195. 2010
  • Risk factor management after acute coronary syndromes..  95:1382-1384. 2009
  • Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients?.  95:1331-1336. 2009
  • Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events..  95:888-894. 2009
  • Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study..  95:570-576. 2009
  • Living arrangement and coronary heart disease: the JPHC study..  95:577-583. 2009
  • Retinopathy predicts coronary heart disease mortality..  95:391-394. 2009
  • ECG interpretation in ST-elevation myocardial infarction: pattern recognition or caliper measurements?.  95:267-268. 2009
  • Defining myocardial infarction: a work in progress: Ischaemic heart disease..  94:1076-1079. 2008
  • Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation..  94:867-873. 2008
  • Echocardiographic risk stratification for early surgery with endocarditis: a cost-effectiveness analysis..  94:e18. 2008
  • Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution..  94:e6. 2008
  • Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes..  94:159-165. 2008
  • Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events..  93:1552-1555. 2007
  • Percutaneous coronary revascularisation: is it ever worth what it costs?.  93:1161-1163. 2007
  • Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups..  93:450-455. 2007
  • Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels..  93:365-367. 2007
  • Atrial myxoma..  93:118. 2007
  • Cardiovascular MRI for detection of myocardial viability and ischaemia..  93:122-129. 2007
  • Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme..  93:59-64. 2007
  • Retinal vascular calibre and the risk of coronary heart disease-related death..  92:1583-1587. 2006
  • Impact of cinematic viewing on endothelial function..  92:261-262. 2006
  • It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarction..  91:1524-1526. 2005
  • Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial..  91:1400-1406. 2005
  • Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns..  91:876-881. 2005
  • Idiopathic ventricular outflow tract tachycardia..  91:136-138. 2005
  • Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough..  90:137-140. 2004
  • Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials..  89:1200-1204. 2003
  • Do guidelines influence practice?.  89:349-352. 2003
  • Endocardial and epicardial steroid lead pacing in the neonatal and paediatric age group..  88:392-396. 2002
  • Vascular and valvar calcification: recent advances..  85:13-17. 2001
  • Images in cardiology. Coronary artery calcification..  84:30. 2000
  • Mobile intracardiac calcinosis: risk of thromboembolism in patients with haemodialysed end stage renal disease..  83:582-583. 2000
  • Left atrial appendage anatomy and function: short term response to sustained atrial fibrillation..  82:555-558. 1999